SYRCELT
LIVE

Serial Number

79373376

Owner

BePharBel Manufacturing S.A.

Attorney

Bradley M. Stohry

Filing Date

Apr 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SYRCELT Trademark

Serial Number: 79373376 • Registration: 7592418

SYRCELT is a trademark filed by BePharBel Manufacturing S.A. on April 7, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

BePharBel Manufacturing S.A.

Rue du Luxembourg 13

Entity Type: 33

Trademark Details

Filing Date

April 7, 2023

Registration Date

December 10, 2024

Published for Opposition

September 10, 2024

Goods & Services

Pharmaceutical products, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases, and pharmaceutical preparations for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents, namely, medicine release agents in the form of gastro-resistant and controlled release microparticles for the controlled release of active ingredients for a wide range of pharmaceutical products; drug delivery agents, namely, medicine delivery agents in the form of granulated powders for the controlled release of active ingredients for a wide range of pharmaceutical products; syrups for pharmaceutical use for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syrups being medicines for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syringes pre-filled with syrups for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines being esomeprazole for oral administration; medicines being omeprazole for oral administration; central nervous system stimulants; hormones for medical use; Pharmaceutical products for the treatment of gastrointestinal disorders; soporifics

Chemical products for use in the pharmaceutical industry, namely, chemical additives and preservatives for use in the manufacture of pharmaceuticals; active chemical ingredients for manufacture of pharmaceutical products for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical additives for use as binding agents in the manufacture of pharmaceuticals for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical carrier excipients for use in the manufacture of pharmaceutical preparations; chemical excipients for the manufacture of pharmaceutical preparations; raw material, namely, cellulose microspheres and microspheres made of cellulose, sugar, and starch for use in the manufacture of pharmaceuticals; microcrystalline cellulose microspheres for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industry, namely, antioxidants and antimicrobials for use in the manufacture of pharmaceuticals; carrier excipients for use in the manufacture of pharmaceutical preparations; excipients for pharmaceutical preparation manufacture

Pharmaceutical research and development for the pharmaceutical industry; medical and pharmacological research services; research and development services relating to medicines; development of pharmaceutical preparations and medicines; development of pharmaceutical products

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 31, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 11, 2025 FICS
FINAL DISPOSITION PROCESSED
May 11, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 10, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 21, 2024 OPNX
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 10, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 4, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 4, 2024 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 10, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 10, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 21, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 7, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 7, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 7, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 7, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 7, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 22, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 22, 2024 TROA
REFUSAL PROCESSED BY IB
Feb 14, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 25, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jan 25, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 9, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jan 8, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 4, 2024 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Sep 8, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Jul 11, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 7, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 6, 2023 REPR